AFFILIATIONS
1 Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
2 Department of Hematology, Bin zhou Medical University Hospital, Binzhou, China
3 Department of Hematology, Shengjing Hospital affiliated to China Medical University, Shenyang, China
4 Department of Hematology, Gansu Provincial Hospital, Lanzhou, China
5 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
6 Department of Hematology, Affiliated Hospital of Chengde Medical University, Chengde, China
7 Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
8 Department of Hematology, Fujian Medical University union hospital, Fuzhou, China
9 Department of Hematology, The Second People's Hospital of Nanyang City, Nanyang, China
10 Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
11 Department of Hematology, Tongji Hospital, Tongji Medical College of HUST, Wuhan, China
12 Xi'an Central Hospital, Xi'an, China
13 Department of Hematology, The First Affiliated Hospital of USTC, Hefei, China
14 CTC Center, West China Hospital, Sichuan University, Chengdu, China
15 Department of Hematology, The Fifth Affiliated Hospital of Anhui Medical University, Fuyang, China
16 Department of Hematology, Yuncheng Central Hospital, Yuncheng, China
17 Department of Hematology, Yantai Yuhuangding Hospital, Yantai, China
18 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
19 Department of Hematology, Deyang People's Hospital, Deyang, China
20 Department of Hematology, Yichang Central People's Hospital, Yichang, China
21 Department of Hematology, Zhanjiang Central People's Hospital, Zhanjiang, China
22 Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
23 Department of Hematology, Puyang People's Hospital, Puyang, China
24 Department of Hematology, Zhongda Hospital Southeast University?, Nanjing, China
25 Department of Hematology, ?The First Affiliated Hospital of Guilin Medical University, Guilin, China
26 Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
27 Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
28 Chengdu Zenitar Biomedical Technology Co., Ltd, Chengdu, China
29 Chengdu Zenitar Biomedical Technology Co., Ltd, Chengdu, China
30 Chengdu Zenitar Biomedical Technology Co., Ltd, Chengdu, China
31 Chengdu Zenitar Biomedical Technology Co., Ltd, Chengdu, China
32 MDS/MPN Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
33 Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
34 MDS/MPN Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
ABSTRACT
Background
Myelofibrosis (MF) is driven by aberrant JAK/STAT signaling, with adverse events, especially cytopenias posing a major clinical challenge that limits the use of standard JAK1/JAK2 inhibitors including ruxolitinib (RUX). Flonoltinib Maleate (FM) is a novel triple-targeted JAK2/FLT3/CDK6 inhibitor with potent anti-MF activity, including platelet level protection and bone marrow fibrosis improvement via suppression of the TGF-β pathway. In the Phase 2b FMF-02 study (NCT06457425) 24-week core treatment, the proportion of patients with reduced spleen volume (SVR35) and improved symptom (TSS50) in both FM high (100mg QD, FMH) and low-dose (50mg QD, FML) cohorts was higher than that of RUX. The SVR35 and TSS50 in FMH, FML and RUX was 96%, 80%, 67%, and 96%, 84%, and 58% respectively. After week 24, patients on RUX were re-randomized to FMH or FML. Here we report the 48-week follow-up efficacy and safety outcomes.
Methods
75 patients with primary MF, post-PV MF, or post-ET MF, DIPSS Int-2 or High risk, were randomized 1:1:1 to FML (50 mg QD), FMH (100 mg QD), or RUX (BID per label) for a 24-week core treatment period. Patients in the RUX arm who completed 24 weeks or had progressive disease due to splenomegaly could cross over to FML or FMH group. Efficacy and safety endpoints were assessed at week 48, including SVR35, TSS50, bone marrow fibrosis improvement, and safety.
Results
As of June 23, 2026, with a median follow-up of 60 weeks, 68 patients (FMH,21,FML,23, RUX-cross over FM,22) (90.7%) entered the extension phase, including 12 and 10 patients crossing over from RUX to FML (RUX-FML) and FMH (RUX-FMH) respectively. At week 48, SVR35 was achieved/maintained in 74% (17/23) in FML and 95% (20/21) in FMH, along with 80% (8/10) in RUX-FML and 100% (9/9) in RUX-FMH. Notably, among the 22 crossover patients, 3 of 5 (60%) who had suboptimal responses to RUX at week 24 achieved SVR35 by week 48, with most of the 19 crossovers showing deeper responses over time. At week 48, TSS50 response rates were 96% (22/23) in FML and 81% (17/21) in FMH, along with 60% (6/10) in RUX-FML and 78% (7/9) in RUX-FMH, with continued durability of symptom improvement observed through long-term follow-up.
Durable dual SVR35 and TSS50 responses were observed in FML and FMH arms, with consistent benefit across subgroups through week 48, including patients with baseline platelet counts <100 × 10?/L (3/3 in FML and 1/1 in FMH achieved dual response at week 48).
Bone marrow fibrosis grade was stable or improved in 86% (19/22), 84% (16/19), 100% (9/9), and 100% (9/9) in FML, FMH, RUX-FML and RUX-FMH cohorts, respectively, among patients with evaluable week 48 biopsies.
Very importantly, long-term safety data revealed no new safety signals. In the FML, FMH, RUX-FML, and RUX-FMH arms, the most common Grade ≥3 hematologic treatment-emergent adverse event (TEAE) was only anemia, with incidences of 4%, 14%, 8%, and 20% in extension period, respectively—markedly lower than rates observed during the initial 24-week period. No Grade ≥3 non-hematologic TEAEs were reported in any of the four arms. Dose reductions due to TEAEs occurred in 13% (3/24), 27% (6/22), 8% (1/12), and 30% (3/10) of patients in the respective cohorts during the extension period, consistent with improved tolerability on long-term treatment.
Conclusions
At week 48, spleen volume and TSS improvements were sustained in both FM cohorts. Patients who switched from RUX to FM after week 24 experienced additional benefits. These findings strongly support the continued development of FM for patients with MF in the ongoing study portfolio.